Navigation Links
UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohn's Disease
Date:10/18/2010

ATLANTA, Oct. 18 /PRNewswire/ -- Findings from the PRECiSE 3 (P3) open label extension study for Cimzia® (certolizumab pegol; CZP), demonstrating the longest continuously running maintenance trial for an anti-TNF in Crohn's disease, will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology (ACG), taking place in San Antonio from October 15 – 20.  Additionally, long-term efficacy data from the PRECiSE 4 (P4) clinical trial also will be presented at the meeting.

Results of the P3 open-label extension study showed that continuous therapy with Cimzia provided long-term remission for more than 4.5 years in patients who initially responded to Cimzia in the six-month PRECiSE 2 study (P2).  In the PRECISE 2 double blind, placebo controlled clinical trial, 48% of patients achieved remission at six months.  Sustained long-term remission was observed among patients who had previous anti-TNF exposure (77% remission), as well as anti-TNF naive patients (73% remission).  

Similarly, results of the P4 open-label extension study showed long-term remission rates among patients treated with Cimzia (naive – 63%; non-naive – 50%).  For some patients, disease remission was achieved in as early as 4 weeks (38% of patient population).  Additionally, the data demonstrates that patients who are losing response to Cimzia or experience an interruption in therapy can be recaptured with one additional dose of Cimzia.  The data suggests re-induction therapy may have long-term benefits in helping patients who experienced drug interruption or loss of initial response achieve response and maintain remission.

"Collectively, these Cimzia data findings are important for patients living with moderate to severe Crohn's disease and the gastroenterologists treating them, as long-term remission is the ultimate goal of treatment," said Cem Kayhan, MD, Medical Director at UCB.  "It
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
3. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
6. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
7. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
8. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
9. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
10. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
11. Wyeth Presents New Phase 3 Data and Updates Regulatory Timing for NDA Filing of Bazedoxifene/Conjugated Estrogens
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... MILFORD, Mass. , Feb. 26, 2015 /PRNewswire/ ... developing novel therapeutics for the treatment of Hepatitis ... announced the closing of a $22 million financing. ... of SB 9200, a novel, broad spectrum antiviral ... molecule nucleic acid hybrid (SMNH) chemistry platform, into ...
(Date:2/26/2015)... Feb. 26, 2015 The market for ... is estimated at 2.4 billion in 2014.   ... growth, government insurance, newly insured patients and updated ... and will continue to propel demand.  The healthcare market ... the market and interviews with IVD manufacturers and ...
(Date:2/26/2015)... -- Editor Note: For more information ... Investor-Edge has initiated coverage on the following equities: ... Pharmaceutical Industries Ltd (NYSE: TEVA ), Endo ... (NYSE: AGN ), and Depomed Inc. (NASDAQ: ... and Johnson can be accessed at http://get.Investor-Edge.com/pdf/?c=Johnson%20and%20Johnson&d=26-Feb-2015&s=JNJ . ...
Breaking Medicine Technology:Spring Bank Pharmaceuticals Completes $22 Million Financing 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 2Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 3Kalorama: Led by Brazil, IVD Test Market in Latin America Exceeds 2 Billion 4Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 2Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 3Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 4Updates on Pharma Stocks -- Johnson and Johnson, Teva Pharma Industries, Endo Intl., Allergan, and Depomed 5
... Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by ...
... Oct. 4 Octapharma USA has ... at www.wilateusa.com to provide von Willebrand disease ... and updates. The U.S. Food and Drug Administration ... wilate® (von Willebrand Factor/Factor VIII Concentrate, Human), the ...
Cached Medicine Technology:Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon 2Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon 3Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon 4Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon 5Materialise Launches SurgiCase(R) Orthopaedics: A Comprehensive, Custom Solution That Assures Best Practices For The Orthopaedic Surgeon 6Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients 2
(Date:2/26/2015)... The COR HEALTH division of Vets ... NY, to offer customers a full line of Topricin® ... safely and effectively address muscle, joint, and nerve pain. ... Access LLC, Montrose, MI, that is dedicated to providing ... BioMedics is a research and development leader in topical ...
(Date:2/26/2015)... February 26, 2015 The Reproductive Science ... their newly renovated office in Lawrenceville, NJ. ... Center of New Jersey’s physicians, and NJ Top Docs, ... care in the areas of infertility and reproductive medicine. ... excellent success rates and providing current, high quality medical ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Beckman Coulter ... of extracellular vesicles and their cargo in cell-to-cell communication,” ... and their relevance for cell-to-cell communication. The webinar is ... 4, 2015 at 8:00am PT. , Every cell in ... vesicles (EVs) , often called “exosomes” or “microvesicles.” These ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Body Well Therapy, ... ten years of delivering high quality mobile massage ... and other regions across the United States. The company has ... a pivotal year as it sets its sights on additional ... office chair massage services. , “We’ve come a long way ...
(Date:2/26/2015)... San Diego, Calif. (PRWEB) February 26, 2015 ... continues to soar as evidenced by a EuroMonitor ... top $6.5 billion in 2018. In response ... Bellus Academy’s Poway campus is launching a barbering ... Muldoon of San Diego’s “The Factory” salon. The ...
Breaking Medicine News(10 mins):Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 2Health News:COR HEALTH Division of Vets Access Partners with Topical BioMedics to Provide Natural Pain Relief Products 3Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 2Health News:RSCNJ Is Celebrating the Reopening of Their Newly Renovated Office 3Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 2Health News:Beckman Coulter Webinar Series Presents Diversity of Extracellular Vesicles and Their Cargo in Cell-to-cell Communication 3Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 2Health News:Body Well Therapy Celebrates 10 Years of Quality Mobile Massage Services 3Health News:Bellus Academy Partners with Renowned Hairstylist D.J. Muldoon to Launch Signature Barbering Program 2
... third quarter 2008 financial results before the market opens on Monday, November ... ... 2008 -- The company also plans to have a corporate overview ... on November 3, 2008 at 11:20 a.m. EST (8:20 a.m. PST). Michael ...
... the genome in the hope of ,finding genetic variants ... the wrong place, new research at the Stanford ,University ... as type-1 diabetes, is an autoimmune ,disease, caused when ... a person,s pancreas. , What triggers that immune response ...
... Voters in,September, As Well As Other Recent Public Polls ... Oct. 30 With only a few,days remaining before ... the Kaiser Family Foundation, writing for the November 6,2008, ... in ten,registered voters say major changes are needed in ...
... 30 AMN Healthcare Services,Inc. (NYSE: AHS ) today announced ... -- Revenue of $315 million, up 5% over last year and ... Company guidance. -- Revenue growth primarily driven by year-over-year volume ... Nurse & Allied and Locum Tenens. -- EPS of $0.28, ...
... Up 71% Versus Prior Year, As ... Company Generates $67.3 Million of Cash from Operating Activities in ... Third Quarter - ... DIEGO, Oct. 30 Gen-Probe Incorporated,(Nasdaq: GPRO ) today reported strong financial results for ...
... Nuvelo, Inc.,(Nasdaq: NUVO ) today announced third quarter ... September 30, 2008, Nuvelo reported a net,loss of $8.5 million ... or $0.27 per share for the same period in 2007. ... net loss of $27.2 million or,$0.51 per share, compared with ...
Cached Medicine News:Health News: Dynavax to Report Third Quarter 2008 Financial Results : -- To Present at Oppenheimer's Healthcare Conference -- 2Health News:Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows 2Health News:Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows 3Health News:Type-1 diabetes not so much bad genes as good genes behaving badly, Stanford research shows 4Health News:Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration 2Health News:Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration 3Health News:Results From Pre-Election Surveys Published in NEJM Show Deep Concerns About State of Health Care With McCain and Obama Supporters Differing Sharply on Directions for New Administration 4Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 2Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 3Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 4Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 5Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 6Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 7Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 8Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 9Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 10Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 11Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 12Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 13Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 14Health News:AMN Healthcare Announces Third Quarter 2008 Results and Updates Full Year Guidance 15Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 2Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 3Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 4Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 5Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 6Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 7Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 8Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 9Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 10Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 11Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 12Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 13Health News:Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance 14Health News:Nuvelo Reports Third Quarter 2008 Financial Results 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: